Slingshot members are tracking this event:
Arrowhead Pharma (ARWR) to Initiate Phase IIA Study in 2016 Evaluating ARC-AAT in Liver Disease Associated With a Genetic Disorder Causing Alpha-1 Antitrypsin Deficiency (AATD)
Slingshot Insights Explained
Sep 06, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase Iia, Arc-aat, Liver Disease, Alpha-1 Antitrypsin Deficiency